Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
<p><strong>Background:</strong> Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help con...
Main Authors: | , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Society of Nephrology
2022
|